AbbVie Inc. (NYSE: ABBV) is a healthcare company, listed on the NYSE. Alpha Stocks Insight has published 7 articles on ABBV since April 29, 2026, most recently "AbbVie Closes $10.9B Apogee Therapeutics Acquisition, Deepening Immunology Pipeline (NYSE: ABBV)" on Thursday, September 3, 2026. Coverage to date spans Health Care and Earnings Report, tracking ABBV's earnings, analyst activity, and material corporate events. New coverage is added each trading day.
Price
$252.17
Today
+0.50%
Mkt Cap
$443.4B
P/E
69.7x
52W High
$267.47
52W Low
$190.75
Data via Finnhub · refreshes hourly · not financial advice
AbbVie's $10.9B Apogee deal adds zumilokibart and APG273 to its immunology pipeline, with accretion expected to begin in 2032 and 2026 EPS guidance reaffirmed.
AbbVie posted $16.99B in Q2 revenue, up 10.2%, but a $0.14/share Apogee dilution nudged full-year EPS guidance down to $13.87-$14.07.
Final Phase 3 CLL14 trial results on a fixed-duration venetoclax combo were presented in Stockholm, adding clinical depth to AbbVie's hematology franchise.
FDA approves AbbVie's pivekimab sunirine for blastic plasmacytoid dendritic cell neoplasm—a rare aggressive blood cancer with no standard therapy options.
European Committee for Medicinal Products recommends approval of MAVIRET (glecaprevir/pibrentasvir) for acute hepatitis C infection treatment.
AbbVie lifted its 2026 EPS guidance to $14.28 after Q1 EPS of $2.65 and $15B in revenue topped estimates, driven by Skyrizi and Rinvoq strength.
AbbVie topped Q1 2026 EPS estimates and lifted its full-year profit outlook, driven by immunology and neuroscience portfolio growth.
Important Legal Disclaimer
This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.
Affiliate disclosure: This site may contain affiliate links to brokerage platforms. If you open an account through one of our links, we may earn a commission at no additional cost to you. Affiliate relationships do not influence our editorial content or stock coverage decisions.
Important Legal Disclaimer: This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.